24. A pharmaceutical composition, comprising:

(a) at least one polynucleotide of a length of 100 nucleotides or less, wherein the polynucleotide comprises a sequence of a binding site for a transcription factor and which is selected from the group consisting of
GATTGCCTGACGTCAGAGAG (SEQ ID NO:8),
GGAATGACGTTCCCTGTG (SEQ ID NO:9),
AGCTATGACGTTCCAAGG (SEQ ID NO:10),
GCTTGATGACTCAGCCGGAA (SEQ ID NO:11),
TCGATCGGGGCGGGGCGAGC (SEQ ID NO:12),
TGCAGATTGCGCAATCTGCA (SEQ ID NO:13),
AGCGGGGGCGAGCGGGGGCG (SEQ ID NO:14),
GTCCATTTCCCGTAAATCTT (SEQ ID NO:16),
TATGCATATTCCTGTAAGTG (SEQ ID NO:17),
CTGATTTCCCCGAAATGATG (SEQ ID NO:19),
AGATTTCTAGGAATTCAATC (SEQ ID NO:20),
GTATTTCCCAGAAAAGGAAC (SEQ ID NO:21),
AAGCGAAAATGAAATTGACT (SEQ ID NO:22), and
CAGGCATAACGGTTCCGTAG (SEQ ID NO:23);

(b) at least one antigen; and

(c) a pharmaceutically acceptable carrier and/or diluent.

Provided claim 24 as amended does read as recited above, Applicant accepts the proposed Examiner's Amendment.

Applicant thanks the Examiner for the proposed amendment. A Notice of Allowance is earnestly solicited. Should the Examiner have any questions, she is requested to call Applicant's representative at the number shown below.